Pfizer (PFE) Short term Debt (2009 - 2026)

Pfizer (PFE) has 18 years of Short term Debt data on file, last reported at $3.9 billion in Q1 2026.

• Quarterly Short term Debt fell 12.98% year-over-year to $3.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 12.98% YoY) and the FY2025 annual result came in at $3.2 billion, down 54.59% from the prior year.
• Short term Debt advanced to $3.9 billion in Q1 2026 per PFE's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Short term Debt topped out at $11.9 billion in Q2 2024 and bottomed at $645.0 million in Q2 2022.
• The 5-year median for Short term Debt is $4.3 billion (2025), against an average of $5.4 billion.
• The widest annual swing landed in 2022, when Short term Debt tumbled 85.18%; it then surged 549.3% in 2023.
• Tracing PFE's Short term Debt over 5 years: stood at $2.9 billion in 2022, then jumped by 251.44% to $10.4 billion in 2023, then slumped by 32.89% to $6.9 billion in 2024, then slumped by 54.59% to $3.2 billion in 2025, then grew by 23.34% to $3.9 billion in 2026.
• Per Business Quant, the three latest PFE Short term Debt figures stand at $3.9 billion (Q1 2026), $3.2 billion (Q4 2025), and $4.3 billion (Q3 2025).

Peer Comparison